Cart is empty A lack of cancer progression could be used as a substitute for overall survival in metastatic hormone-sensitive prostate cancer clinical trials, according to a new meta-analysis published in the Journal of Clinical Oncology, an approach that could accelerate research and allow new treatments to reach patients faster.
Leave A Comment